title: Enhanced sensitivity to tumor growth and development in multistage skin carcinogenesis by transforming growth factor-alpha-induced epidermal growth factor receptor activation but not p53 inactivation.
abstract: Transforming growth factor-alpha (TGF alpha) can stimulate keratinocyte proliferation and function as an autocrine tumor promoter in 7,12-dimethylbenz[a]anthracene (DMBA)-initiated TGF alpha-transgenic mouse skin. In this study, we examined the effect of ectopic TGF alpha transgene expression on skin tumor growth and progression after DMBA initiation in the presence of 12-O-tetradecanoylphorbol-13-acetate (TPA). Both the multiplicity and size of skin tumors arising in TGF alpha-transgenic mice were significantly higher than those of the nontransgenic parental CD-1 strain. There were more dysplastic papillomas and squamous cell carcinomas (SCCs) in the transgenic animals as well. ProTGF alpha protein was expressed in transgenic papillomas, but mature TGF alpha was not detected. The epidermal growth factor receptor (EGFR) appeared to be downregulated and was associated with enhanced tyrosine phosphorylation of several substrates in TGF alpha-transgenic mouse tumors. Characteristic codon 61 mutations in the Ha-ras gene were found in most of the papillomas and SCCs induced by DMBA and TPA in transgenic as well as nontransgenic mice. However, no p53 gene mutations were found in any skin tumors from either transgenic or control animals. Analysis of cellular proliferation in both DMBA-TPA-induced papillomas and in skin 48 h after TPA treatment alone revealed significantly more DNA synthesis in TGF alpha-transgenic mice relative to controls. These results demonstrate that TGF alpha, through EGFR overstimulation, can act synergistically with TPA to induce the formation, growth, and development of DMBA-initiated skin tumors containing classic Ha-ras gene mutations but not p53 gene inactivation.
authors.affiliation: Veterinary and Tumor Pathology Section, National Cancer Institute, Frederick, Maryland 21702-1201, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Shibata
authors.forename: J M
authors.initials: JM
authors.lastname: Ward
authors.forename: J E
authors.initials: JE
authors.lastname: Green
authors.forename: G
authors.initials: G
authors.lastname: Merlino
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D002273:Carcinogens; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000235:genetics / Q000473:pathology*; D003001:Cloning, Molecular; D066246:ErbB Receptors / Q000096:biosynthesis*; D005091:Exons; D016158:Genes, p53; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D010212:Papilloma / Q000139:chemically induced / Q000235:genetics / Q000473:pathology*; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011994:Recombinant Proteins / Q000096:biosynthesis; D012867:Skin / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced / Q000235:genetics / Q000473:pathology*; D016211:Transforming Growth Factor alpha / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D002273:Carcinogens; D011994:Recombinant Proteins; D016211:Transforming Growth Factor alpha; D015127:9,10-Dimethyl-1,2-benzanthracene; D066246:ErbB Receptors